Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22036847 | 0.88 | CHRM2 (0.38) | BRD4BRD2CHRM2CHRM3NEK2 | |
| SCHEMBL16189947 | 0.87 | BRD4 (0.41) | BRD4BRD2ALDH1A1 | |
| SCHEMBL7288250 | 0.79 | ALDH1A1 (0.40) | BRD4BRD2ALDH1A1PRMT1 | |
| SCHEMBL4103157 | 0.77 | ALDH1A1 (0.39) | BRD4BRD2ALDH1A1PRMT1 | |
| SCHEMBL10186802 | 0.76 | — | — | |
| SCHEMBL10186800 | 0.76 | ALDH1A1 (0.36) | BRD4BRD2CHRM2CHRM3NEK2 | |
| SCHEMBL16189948 | 0.73 | — | — | |
| SCHEMBL2743221 | 0.71 | CHRM2 (0.46) | BRD4BRD2CHRM2CHRM3NEK2 | |
| SCHEMBL7357702 | 0.70 | ALDH1A1 (0.40) | BRD4BRD2ALDH1A1PRMT1 | |
| SCHEMBL13516651 | 0.70 | BRD4 (0.41) | BRD4BRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | BRD4 799/4885BRD2 334/4885CHRM2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.